Cita APA

Querol, L., Lewis, R. A., Hartung, H., van Doorn, P., Wallstroem, E., Luo, X., . . . Hughes, R. (2023). An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy.

Citación estilo Chicago

Querol, Luis|||0000-0002-4289-8264, Richard Alan|||0000-0002-1140-4575 Lewis, H.P Hartung, Pieter|||0000-0003-2584-3357 van Doorn, E. Wallstroem, Xiaodong|||0000-0002-8214-9874 Luo, Miguel|||0000-0003-3372-9933 Alonso-Alonso, Nazem Atassi, y Richard|||0000-0001-5251-3797 Hughes. An Innovative Phase 2 Proof-of-concept Trial Design to Evaluate SAR445088, a Monoclonal Antibody Targeting Complement C1s in Chronic Inflammatory Demyelinating Polyneuropathy. 2023.

Cita MLA

Querol, Luis|||0000-0002-4289-8264, et al. An Innovative Phase 2 Proof-of-concept Trial Design to Evaluate SAR445088, a Monoclonal Antibody Targeting Complement C1s in Chronic Inflammatory Demyelinating Polyneuropathy. 2023.